Sandbox/AL: Difference between revisions
Blanked the page |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Tenecteplase}} | |||
{{CMG}}; {{AE}} {{SS}} | |||
{{SB}} TNKASE<sup>®</sup> | |||
==Overview== | |||
'''Tenecteplase (TNK)''' is an [[enzyme]] used as a [[thrombolytic drug]]. | |||
Tenecteplase is a [[tissue plasminogen activator]] (tPA) produced by recombinant DNA technology using an established mammalian cell line (Chinese hamster ovary cells). Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296–299 in the protease domain. | |||
Tenecteplase is a recombinant fibrin-specific plasminogen activator that is derived from native t-PA by modifications at three sites of the protein structure. It binds to the fibrin component of the thrombus (blood clot) and selectively converts thrombus-bound plasminogen to plasmin, which degrades the fibrin matrix of the thrombus. Tenecteplase has a higher fibrin specificity and greater resistance to inactivation by its endogenous inhibitor (PAI-1) compared to native t-PA. | |||
==Category== | |||
Cardiovascular Drugs:Thrombolytic drugs | |||
==FDA Package Insert== | |||
'''| [[Tenecteplase indications and usage|Indications and Usage]]''' | |||
'''| [[Tenecteplase dosage and administration|Dosage and Administration]]''' | |||
'''| [[Tenecteplase contraindications|Contraindications]]''' | |||
'''| [[Tenecteplase warnings and precautions|Warnings and Precautions]]''' | |||
'''| [[Tenecteplase adverse reactions|Adverse Reactions]]''' | |||
'''| [[Tenecteplase drug interactions|Drug Interactions]]''' | |||
'''| [[Tenecteplase use in specific populations|Use in Specific Populations]]''' | |||
'''| [[Tenecteplase description|Description]]''' | |||
'''| [[Tenecteplase clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[Tenecteplase nonclinical toxicology|Nonclinical Toxicology]]''' | |||
'''| [[Tenecteplase clinical studies|Clinical Studies]]''' | |||
'''| [[Tenecteplase how supplied storage and handling|How Supplied/Storage and Handling]]''' | |||
'''| [[Tenecteplase labels and packages|Labels and Packages]]''' | |||
==Mechanism of Action== | |||
==References== | |||
{{Reflist|2}} | |||
{{Antithrombotics}} | |||
[[Category:Thrombolytic drugs]] | |||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Drugs]] | |||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} | |||
Revision as of 18:54, 11 July 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Synonyms / Brand Names: TNKASE®
Overview
Tenecteplase (TNK) is an enzyme used as a thrombolytic drug.
Tenecteplase is a tissue plasminogen activator (tPA) produced by recombinant DNA technology using an established mammalian cell line (Chinese hamster ovary cells). Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296–299 in the protease domain.
Tenecteplase is a recombinant fibrin-specific plasminogen activator that is derived from native t-PA by modifications at three sites of the protein structure. It binds to the fibrin component of the thrombus (blood clot) and selectively converts thrombus-bound plasminogen to plasmin, which degrades the fibrin matrix of the thrombus. Tenecteplase has a higher fibrin specificity and greater resistance to inactivation by its endogenous inhibitor (PAI-1) compared to native t-PA.
Category
Cardiovascular Drugs:Thrombolytic drugs
FDA Package Insert
| Indications and Usage | Dosage and Administration | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Labels and Packages